{"anticipatedPostingDate":"2027-12","denomUnitsSelected":"Participants","description":"CTCAE version 5.0 Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.","reportingStatus":"NOT_POSTED","timeFrame":"From the date of first dose up to 90 days after last dose or new anticancer therapy whichever occurred first (up to approximately 20.14 months)","title":"Number of Participants With Shift From Grade Less Than or Equal to (<=) 2 at Baseline to Grade 3 or 4 Post -Baseline in Laboratory Parameters by NCI CTCAE v 5.0","type":"SECONDARY"}